H55 RECOGNIZED AMONG FAST COMPANY'S MOST INNOVATIVE COMPANIES OF 2025
SION, Switzerland , March 31, 2025 /CNW/ -- H55, a leader in electric aviation solutions, is honored to announce its inclusion in Fast Company's esteemed list of the World's Most Innovative Companies of 2025, securing the No. 10 position in the transportation category. This recognition underscores H55's commitment to advancing electric propulsion and battery storage technologies, building upon the team's heritage of Solar Impulse.
Fast Company's annual list highlights businesses that are reshaping industries and culture through innovation. This year, over 600 organizations across 58 sectors were recognized for setting new standards and achieving remarkable milestones.
H55's mission is to revolutionize air travel by providing certified electric propulsion and battery management systems tailored to a diverse range of aircraft, thereby realizing sustainable aviation. The company's flagship electric propulsion system integrates electric propulsion and battery storage, offering quiet operation, low operational costs, and zero-emissions.
In 2024, H55 achieved significant milestones, including the acceptance of its battery pack Compliance Checklist by the European Union Aviation Safety Agency (EASA), marking a critical step toward certification. Additionally, the company introduced the B23 Energic, a fully electric two-seater developed in partnership with Czech airplane manufacturer BRM Aero. The aircraft can remain aloft for over an hour on a single charge, with recharging costs averaging just $7 .
As part of its ongoing efforts to demonstrate the viability of electric aviation, H55 is embarking on the "Across America" tour. Commencing at SUN 'n FUN in Lakeland, Florida , this five-month journey will showcase the B23 Energic across major aviation hubs and events throughout the United States , including stops in Florida , Arizona , California , Nevada , Colorado , Wisconsin (EAA AirVenture) and New York . The tour invites flight schools, government agencies, investors, and aviation professionals to experience the future of electric flight firsthand.
Reflecting on this recognition, André Borschberg, Co-Founder and Executive Chairman of H55, stated: "Being recognized by Fast Company as one of the world's most innovative companies is a meaningful validation of our vision. It reinforces the pioneering work that began with Solar Impulse and continues today with H55. As we embark on the 'Across America' tour, we are not just showcasing technology—we are proving what is possible. Pilots, industry leaders, and regulators will be able to experience firsthand the efficiency, reliability, and sustainability of electric flight. With this mission, we're demonstrating that electric aviation is no longer a distant dream—it is a certified, commercially viable solution ready to be adopted by operators and transform the way we fly."
Commenting on H55's technical progress and path to market readiness, Martin Larose, CEO of H55, "The company is advancing steadily toward certification. Our technology has been thoroughly de- risked, and we're making strong progress on key milestones, with battery certification requirements expected to be completed by mid-2025, followed by full electric propulsion system approvals in Europe , the United States , and Canada . We remain committed to advancing electric aviation with precision and purpose, staying true to the values that guide our innovation."
As global momentum builds around clean aviation, H55's recognition by Fast Company reinforces its leadership at the intersection of innovation and sustainability. With a clear certification path and a bold roadmap ahead, the company is helping shape an era where electric flight becomes the new norm.
The full list of Fast Company's Most Innovative Companies honorees is available at fastcompany. com and on newsstands beginning March 25 . Fast Company will host the Most Innovative Companies Summit and Gala for honorees on June 5 , featuring a day of inspiring content followed by a creative black-tie gala.
For more information about H55 and its initiatives, please visit www.h55.ch.
About H55
H55 is a Swiss-based company founded by the former Solar Impulse management team: André Borschberg, Sebastien Demont , and Gregory Blatt. Dedicated to revolutionizing the aviation industry, H55 provides certified electric propulsion and battery management systems tailored to a diverse range of aircraft, aiming to achieve sustainable air travel. Through its pioneering legacy and commitment to certified solutions, H55's team of visionary engineers and aerospace experts are at the forefront of driving the aviation industry toward a more environmentally responsible future, setting new standards and pushing the boundaries of electric aviation.
Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with fellow business publication Inc. For more information, please visit fastcompany.com.
For more information
press@h55.ch
www.h55.ch
H55 SA
Route de l'Aéroport 10 1950 Sion
Switzerland
SOURCE H55
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
25 minutes ago
- Cision Canada
Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹ Français
KIRKLAND, QC, July 21, 2025 /CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. 1,2 The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients randomized to KEYTRUDA ® in combination with CRT compared with patients randomized to placebo plus CRT. 3 "The approval of KN-A18 is an important addition to the treatment of gynecological cancers, as it has demonstrated a statistically significant improvement in overall survival and progression-free survival in patients with FIGO 2014 Stage III-IVa," stated Shannon Salvador, Gynecologic Oncologist at the Jewish General Hospital and President of the Society of Gynecologic Oncology of Canada. 4"This recent approval adds another therapeutic option for patients in an important disease space." "This approval marks a pivotal moment for patients, as it represents the first indication in Canada for KEYTRUDA ® in combination with chemoradiotherapy," said André Galarneau, PhD, Executive Director & Vice President, Oncology Business Unit at Merck Canada. "Reaffirming our commitment to cervical cancer, we are eager to continue expanding treatment options for patients impacted by this disease." 5 About KEYNOTE-A18 / ENGOT-cx11/GOG-3047 KEYNOTE-A18 is a multicenter, randomized, double-blind, placebo-controlled phase III trial ( NCT04221945). 2 The trial investigated the efficacy of pembrolizumab in combination with CRT (cisplatin and external beam radiation therapy [EBRT] followed by brachytherapy [BT]) for the treatment of patients with locally advanced cervical cancer. 1 The trial enrolled 1,060 newly diagnosed patients with locally advanced squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the cervix defined as FIGO 2014 stage IB2 to IIB with positive lymph nodes or stage III to IVA regardless of nodal status. 3 There were 599 patients with FIGO 2014 Stage III-IVA. Randomization was stratified by planned type of EBRT (Intensity modulated radiation therapy [IMRT] or volumetric modulated arc therapy [VMAT] vs. non IMRT and non VMAT), stage at screening of cervical cancer (FIGO 2014 Stage IB2 IIB vs. FIGO 2014 Stage III-IVA), and planned total radiotherapy dose (EBRT + brachytherapy dose of <70 Gy vs. ≥70 Gy as per equivalent dose [EQD2]). 1 Patients were randomized (1:1) to one of two treatment arms: Pembrolizumab 200 mg IV every 3 weeks (5 cycles) concurrent with cisplatin 40 mg/m2 IV weekly (5 cycles, an optional sixth infusion could be administered per local practice) and radiotherapy (EBRT followed by BT), followed by pembrolizumab 400 mg IV every 6 weeks (15 cycles). 1,3 Placebo IV every 3 weeks (5 cycles) concurrent with cisplatin 40 mg/m2 IV weekly (5 cycles, an optional sixth infusion could be administered per local practice), and radiotherapy (EBRT followed by BT), followed by placebo IV every 6 weeks (15 cycles). 1,3 Treatment continued until RECIST (Response Evaluation Criteria in Solid Tumors) v1.1-defined progression of disease as determined by investigator or unacceptable toxicity. 1 Assessment of tumour status was performed every 12 weeks from completion of CRT for the first two years, followed by every 24 weeks in year 3, and then annually. The major efficacy outcome measures were PFS as assessed by investigator according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, or histopathologic confirmation, and OS. 1 The trial demonstrated statistically significant improvements in both PFS (HR (Hazard Ratio) 0.70; 95% CI (confidence interval): 0.55–0.89; p = 0.002) and OS (HR 0.67; 95% CI: 0.50–0.90; p = 0.004) in the overall population. In an exploratory subgroup analysis for the 459 patients (43%) with FIGO 2014 Stage IB2–IIB disease, the PFS and OS HR estimates were 0.91 (95% CI: 0.63–1.32) and 0.89 (95% CI: 0.55–1.44), respectively, suggesting that the improvements in PFS and OS observed in the overall population were primarily driven by the later-stage subgroup of patients with FIGO 2014 Stage III–IVA disease. The efficacy results in the exploratory subgroup analysis of 599 patients with FIGO 2014 Stage III-IVA disease showed that pembrolizumab plus CRT demonstrated improvements in PFS (Hazard Ratio (HR) 0.59; 95% CI 0.43, 0.81) and OS (HR 0.58; 95% CI 0.40, 0.85) in the overall population. 1 For the FIGO 2014 Stage III-IVA population, the most common treatment-related adverse events (reported in at least 20% of patients) were anemia, nausea, diarrhea, white blood cell count decreased, neutrophil count decreased, vomiting, platelet count decreased, and hypothyroidism. 6 For complete information, refer to the KEYTRUDA ® product monograph. About cervical cancer Cervical cancer forms in the cells lining the cervix, which is the lower part of the uterus. 7 Despite concerted efforts in screening and prevention across Canada, cervical cancer has become the fastest growing cancer type in females. 8,9 In 2024 alone, it was estimated that there were approximately 1,600 women diagnosed with cervical cancer and an estimated 400 deaths as a result of the disease. 10 About KEYTRUDA ® KEYTRUDA ® is an anti-programmed death receptor-1 (anti-PD-1) therapy that works by helping increase the ability of the body's immune system to help detect and fight tumour cells. KEYTRUDA ® is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumour cells and healthy cells. 11,12,13 KEYTRUDA ® was first approved in Canada in 2015 and currently has indications in several disease areas, including advanced renal cell carcinoma, bladder cancer, non-small cell lung carcinoma, primary mediastinal B-cell lymphoma, classical Hodgkin lymphoma, colorectal cancer, endometrial carcinoma, cervical cancer, esophageal cancer, triple-negative breast cancer, melanoma, and head and neck squamous cell carcinoma. 14 About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit and connect with us on LinkedIn @MerckCanada. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( ® Merck Sharp & Dohme LLC. Used under license. © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. CA-NON-04142 1 KEYTRUDA ® Product Monograph, page 285-286. 2 3 The ASCO Post. KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy. 4 Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial, page 1329. 5 6 KEYTRUDA ® Product Monograph, page 146. 7 Canadian Cancer Society. What is cervical cancer? 8 Canadian Cancer Statistics 2023, page 22. 9 Canadian Cancer Statistics 2023, page 80. 10 Canadian Cancer Society. Cervical cancer statistics. 11 KEYTRUDA ® Product Monograph, page 300. 12 KEYTRUDA ® Product Monograph, page 188. 13 KEYTRUDA ® Product Monograph, page 192. 14 KEYTRUDA ® Product Monograph, pages 1-3. Media Contacts: Merck Canada Media Relations 1-833-906-3725 [email protected]
Cision Canada
25 minutes ago
- Cision Canada
Delaine A. Deer Launches "Voice of Impact", a 12-Session Leadership Program for Women in Male-Dominated Industries
Built for real-world leadership, the program equips marginalized women with the strategy, confidence, and community to rise without burnout or compromise NEW YORK, July 21, 2025 /CNW/ -- Delaine A. Deer, leadership coach and founder of ProWorks Hive, has launched Voice of Impact, a 12-session coaching program designed for women ready to lead in industries where their voices have long been underrepresented—construction, tech, and corporate leadership. Despite growing conversations around diversity, women—especially women of color and LGBTQ+ professionals—continue to face barriers. Only 10% of construction executives are women (BLS, 2023), nearly half of women in tech report workplace discrimination (Pew, 2023), and Black women are promoted at just 58% the rate of white men (Lean In, 2023). Voice of Impact addresses these disparities directly, offering practical tools, coaching, and community to help women break through bias and lead with impact. The program is a systems-level response to leadership inequality. Designed by Deer with support from industry advisors, Voice of Impact equips women with actionable strategies to apply immediately in their careers. The experience blends expert coaching, leadership development, and continuous support via the ProWorks Hive platform—an exclusive online network for peer engagement and mentorship. "For too long, women have been told to 'lean in.' But without the tools to navigate systemic bias, that's not enough," said Deer. "Voice of Impact gives them the skills, strategy, and support to not only claim their seat at the table—but to thrive in it." Participants in the inaugural cohort receive founding member status and lifetime access to ProWorks Hive. Program modules cover leadership branding, confident communication, negotiating promotions, and building a bias-resistant mindset. About Delaine A. Deer and ProWorks Hive Delaine A. Deer is a leadership coach, speaker, and founder of ProWorks Hive. With 20+ years of experience in project leadership and inclusive development, she helps women and marginalized professionals lead with clarity, confidence, and systemic impact. ProWorks Hive is a leadership accelerator that supports professionals navigating male-dominated spaces through coaching, community, and strategic career insight. Voice of Impact inaugural cohort.
Cision Canada
25 minutes ago
- Cision Canada
Brenda Buchanan appointed CEO of RECO, Ontario's regulator of real estate services
She brings decades of leadership and regulatory experience including in her previous role as RECO's Chief Operations Officer TORONTO, July 21, 2025 /CNW/ - The board of directors of the Real Estate Council of Ontario (RECO) is pleased to announce the appointment of Brenda Buchanan as Chief Executive Officer effective immediately. This follows a comprehensive national search to identify a leader to guide RECO into the future as a strong regulator committed to pursuing trust in every transaction. Ms. Buchanan is an accomplished and empathetic leader who brings to the CEO role deep experience, strong support for team and stakeholder engagement, and an unwavering commitment to consumer protection. She has more than 20 years of experience in the Ontario regulatory environment and has held senior positions in both public and private sector organizations. "We are proud to welcome Brenda as RECO's new CEO," said Katie Steinfeld, Chair of RECO's board. "Brenda is a bold, forward-thinking leader whose vision and drive will lead RECO into a new era of innovation, transparency, and consumer trust. Her appointment marks an exciting chapter for RECO as we embrace change and reimagine the future of real estate regulation in Ontario." "I am honoured to continue to lead the RECO team as we build on our momentum as a consumer-focused, forward looking and technology-enabled regulator," said Ms. Buchanan. "I'm excited to deepen our collaboration with the Ontario government, and our stakeholders, as we work together to support the real estate profession and ensure strong consumer protection." Following the retirement of the previous CEO in February 2025, RECO's board named Ms. Buchanan as Interim CEO in February 2025, following a six-year tenure as the organization's Chief Operations Officer. About RECO The Real Estate Council of Ontario (RECO) is a not-for-profit organization that regulates real estate agents and brokerages across the province. Its mission is to protect consumers by ensuring that real estate agents, brokers, and brokerages understand and comply with the law. An important aspect of RECO's mandate is to educate consumers about their rights and responsibilities, including publishing the RECO Information Guide, which agents and brokers are required to share with every prospective client or self-represented party. About RECO Chief Executive Officer Brenda Buchanan Brenda Buchanan is the Chief Executive Officer of the Real Estate Council of Ontario. She is an accomplished and collaborative leader who brings to the CEO role deep experience, strong support for team and stakeholder engagement, and an unwavering commitment to consumer protection. Prior to assuming the CEO role in 2025, Brenda was Chief Operations Officer and a member of RECO's senior management team beginning in 2019, where she led the strategic and business planning process alongside accountability for core functions including stakeholder relations, finance and accounting, information technology, human resources, facilities, client services, and discipline and appeals hearings. She was appointed Interim CEO in February 2025. Before joining RECO, Brenda served over 12 years with an Ontario-based industry regulator in various executive roles. She was an executive with the Canada Lands Company, a federal crown corporation, as well as other progressively senior positions in both public and private sector organizations spanning the consulting and construction management sectors. A former board member of the Starlight Children's Foundation and a frequent community volunteer, she has also been an advisory committee member for the human resources program at George Brown College. Brenda is a graduate of the University of Guelph.
